

COMIRNATY CLINICAL TRIAL

	Comirnaty	Placebo	Absolute/Relative Effectiveness
Group size	22,030	22,030	
Adverse Events	6,609 30.00%	3,084 14.00%	-114% -16.00%
Severe Adverse Events	264.36 1.20%	154.21 0.70%	-71% -0.50%
Cases (with prior infection)	2 0.01%	7 0.03%	71% 0.02%
Severe Cases	1 0.00%	30 0.14%	97% 0.13%
Deaths	15 0.07%	14 0.06%	-7% 0.00%
Severe Adverse Events / Severe Cases	14x		
Severe Adverse Events / Cases (with prior infection)	47x		

<https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf>

EARLY TREATMENT

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

<https://pubmed.ncbi.nlm.nih.gov/16115318/>

Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2

<https://pubmed.ncbi.nlm.nih.gov/32643111/>

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin
in the Prophylaxis and Treatment of COVID-19

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/>

Monoclonal Antibodies

<https://www.coronaviruspreventionnetwork.org/monoclonal-antibodies/>